论文部分内容阅读
罗氏(Roche)远东有限公司于1983年2月开始在香港和澳门试销治疗牛皮癣和角化不良的特效口服药,名为Etretinate(Tigason),此药是维生素A酸的芳香族同类物。新加坡和马来西亚已于早些时候试销Tigason。英国和欧洲已使用约一年,剂型为10mg和25mg胶囊两种。 Etretinate是瑞士罗氏药厂的维生素A产品,从1,500种以上维生素A酸衍生物中选出。此药是首次用于治疗牛皮癣和严重角化不良的一种口服药,可与类固醇药物问
Roche Far East Ltd. began trial marketing in February 1983 in Hong Kong and Macau for the treatment of psoriasis and dyskeratotic oral specialties called Etretinate (Tigason), an aromatic congener of vitamin A acid. Singapore and Malaysia have been trying Tigason earlier. Approximately one year has been used in Britain and Europe, with two dosage forms, 10 mg and 25 mg. Etretinate is a vitamin A product from Roche Pharmaceuticals, Switzerland, and is selected from more than 1,500 vitamin A acid derivatives. This medicine is the first oral medication for the treatment of psoriasis and severe dyskeratosis and can be used with steroid medications